# Lakefront Biotherapeutics (LKFT) — Analyst Forecast

LKFT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lkft/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 4 | 4 | 1 | 9 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 23, 2026 | RBC Capital | Upgraded | Sector Perform → Outperform | $45.00 |
| Aug 11, 2026 | RBC Capital | Maintained | Sector Perform | $26.00 |
| Aug 11, 2026 | Morgan Stanley | Maintained | Equal-Weight | $26.00 |
| Feb 25, 2026 | RBC Capital | Maintained | Sector Perform | $33.00 |
| Nov 7, 2025 | RBC Capital | Maintained | Sector Perform | $32.00 |
| Oct 22, 2025 | RBC Capital | Maintained | Sector Perform | $28.00 |
| Oct 21, 2025 | Leerink Partners | Upgraded | Market Perform → Outperform | $40.00 |
| Feb 14, 2025 | Morgan Stanley | Downgraded | Equal-Weight → Underweight | $22.00 |
| Jan 23, 2025 | Barclays | Downgraded | Equal-Weight → Underweight | — |
| Nov 1, 2024 | RBC Capital | Maintained | Sector Perform | $30.00 |
| Sep 9, 2024 | Leerink Partners | Initiated Coverage | Market Perform | $24.00 |
| Apr 22, 2024 | Morgan Stanley | Maintained | Equal-Weight | $38.00 |
| Apr 1, 2024 | B of A Securities | Downgraded | Neutral → Underperform | $31.00 |
| Mar 28, 2024 | B of A Securities | Downgraded | Neutral → Underperform | $31.00 |
| Mar 7, 2024 | Morgan Stanley | Initiated Coverage | Equal-Weight | $38.00 |
| Jan 2, 2024 | B of A Securities | Maintained | Neutral | $44.00 |
| Aug 7, 2023 | Morgan Stanley | Maintained | Equal-Weight | $40.00 |
| Aug 1, 2023 | Morgan Stanley | Maintained | Equal-Weight | $42.00 |
| Jul 31, 2023 | Morgan Stanley | Maintained | Equal-Weight | $42.00 |
| Jul 24, 2023 | Morgan Stanley | Maintained | Equal-Weight | $42.00 |

## Frequently Asked Questions

### Is LKFT a buy, sell, or hold?

Analysts covering Lakefront Biotherapeutics currently average a Buy rating: 4 buy, 4 hold and 1 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on LKFT?

On Sep 23, 2026, RBC Capital upgraded Lakefront Biotherapeutics to Outperform with a price target of $45.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).